Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuolung Hu

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|June 1, 2017
Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndromeGuoqing Diao, Donglin Zeng, Kuolung Hu, et al.
Biometrics|May 21, 2019
Semiparametric frailty models for zero-inflated event count data in the presence of informative dropoutGuoqing Diao, Donglin Zeng, Kuolung Hu, et al.
Journal of Biopharmaceutical Statistics|November 28, 2017
Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarityDonglin Zeng, Jean Pan, Kuolung Hu, et al.
Statistics in Medicine|March 27, 2015
Hypothesis testing for two-stage designs with over or under enrollmentDonglin Zeng, Fei Gao, Kuolung Hu, et al.
Advances in Therapy|November 23, 2016
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical DataArie Barlev, Vincent W Lin, Aaron Katz, et al.
Journal of Biopharmaceutical Statistics|March 11, 2014
Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndromeDonglin Zeng, Joseph G Ibrahim, Ming-Hui Chen, et al.
Biometrics|October 22, 2019
Bayesian design of biosimilars clinical programs involving multiple therapeutic indicationsMatthew A Psioda, Kuolung Hu, Yang Zhang, et al.
Biometrics|July 22, 2014
Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndromeMing-Hui Chen, Joseph G Ibrahim, Donglin Zeng, et al.
Diabetes Care|October 27, 2005
The effect of ruboxistaurin on nephropathy in type 2 diabetesKatherine R Tuttle, George L Bakris, Robert D Toto, et al.
Leukemia & Lymphoma|August 22, 2012
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabinePeter L Greenberg, Guillermo Garcia-Manero, Michael Moore, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|June 1, 2017
Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndromeGuoqing Diao, Donglin Zeng, Kuolung Hu, et al.
Biometrics|May 21, 2019
Semiparametric frailty models for zero-inflated event count data in the presence of informative dropoutGuoqing Diao, Donglin Zeng, Kuolung Hu, et al.
Journal of Biopharmaceutical Statistics|November 28, 2017
Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarityDonglin Zeng, Jean Pan, Kuolung Hu, et al.
Statistics in Medicine|March 27, 2015
Hypothesis testing for two-stage designs with over or under enrollmentDonglin Zeng, Fei Gao, Kuolung Hu, et al.
Advances in Therapy|November 23, 2016
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical DataArie Barlev, Vincent W Lin, Aaron Katz, et al.
Journal of Biopharmaceutical Statistics|March 11, 2014
Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndromeDonglin Zeng, Joseph G Ibrahim, Ming-Hui Chen, et al.
Biometrics|October 22, 2019
Bayesian design of biosimilars clinical programs involving multiple therapeutic indicationsMatthew A Psioda, Kuolung Hu, Yang Zhang, et al.
Biometrics|July 22, 2014
Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndromeMing-Hui Chen, Joseph G Ibrahim, Donglin Zeng, et al.
Diabetes Care|October 27, 2005
The effect of ruboxistaurin on nephropathy in type 2 diabetesKatherine R Tuttle, George L Bakris, Robert D Toto, et al.
Leukemia & Lymphoma|August 22, 2012
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabinePeter L Greenberg, Guillermo Garcia-Manero, Michael Moore, et al.
Pageof 2